Одна из главных задач Life4me+ — предотвращение новых случаев заражения ВИЧ-инфекцией и другими ИППП, гепатитом C и туберкулезом.

Приложение позволяет установить анонимную связь между врачами и ВИЧ-позитивными людьми, дает возможность организовать своевременный прием ваших медикаментов, получать замаскированные напоминания о них.

16 января 2014, 00:00

К 2016 году Tivicay (dolutegravir) компании ViiV может стать ведущим препаратом для лечения ВИЧ

К 2016 году Tivicay (dolutegravir) компании ViiV может стать ведущим препаратом для лечения ВИЧ - изображение 1

Antiretroviral drug Tivicay (dolutegravir) is set to become the leading integrase inhibitor for the treatment of HIV by 2016, according to independent analyst firm Datamonitor Healthcare.

Tivicay is marketed by ViiV Healthcare, the HIV/AIDS joint venture by GlaxoSmithKline (LSE: GSK) with Pfizer (NYSE: PFE) and Shionogi (TYO: 4507). In November it was approved in Canada after being approved by the US Food and Drug Administration in the summer. Datamonitor analysts say it is expected to generate annual sales of up to $2.1 billion by 2022 in the USA, Japan and five major EU markets of France, Germany, Italy, Spain and the UK, equating to 12.6% of the total combined value of these markets.

Better efficacy than Prezista or Isentress

Tivicay had better efficacy than the protease inhibitor Prezista (darunavir), from Johnson & Johnson’s (NYSE: JNJ) Janssen Therapeutics division, in clinical trials, and comparable efficacy with current integrase inhibitor standard of care Merck & Co’s (NYSE: MRK) Isentress (raltegravir). It is predicted that the drug will have a huge impact on the market following EU approval.

Joseph Hedden, analyst at Datamonitor Healthcare, said: “Unlike a number of its competitors, Tivicay doesn’t require co-dosing with a boosting agent. It also has a very attractive resistance profile. In the next few years, we are expecting these attributes to propel the drug into first place in terms of integrase inhibitor sales.”

Global HIV sales will reach $17.3 billion in 2020

The combined sales value of HIV drugs in the seven major markets is expected to increase by 40% in the next decade, rising from $11.9 billion in 2013 to $16.8 billion in 2022. It is forecast that the market will peak at $17.3 billion in 2020 after a strong period of growth stimulated by new drug launches and the increasing prevalence of HIV.

Between the forecast dates, the global patient population for HIV is expected to increase slowly, from 1.23 million in 2013 to just under 1.4 million in 2022. Out of the five major EU markets, the UK will remain largest by patient number over the next decade, with the patient population estimated to be 135 million by 2022. The projected annual growth rate for the UK is 6.2%, the fastest of all the major markets.

Поделиться в соцсетях